Health-Medical-Fitness-Diet-zk: Sequencing

duminică, 11 decembrie 2011

First Genome Sequencing Clinical Trial For Triple Negative Cancer Points To New Treatments

Main Category: Breast Cancer
Also Included In: Genetics
Article Date: 11 Dec 2011 - 0:00 PST

email to a friend printer friendly opinions
not yet rated
Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported during the CRTC-AACR San Antonio Breast Cancer Symposium.

The results indicate activation of targets not previously associated with triple negative disease and could point toward new treatment strategies. Based on mutations uncovered by sequencing, physicians recommended the women enter treatment protocols for either existing drugs or new agents being evaluated in pharma-sponsored clinical trials.

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin® (trastuzumab).

Of eleven tumors sequenced to date, each was genomically unique, but commonalities were observed. Some patients displayed amplified genes in the RAS pathway; one patient had amplification of the BRAF oncogene, as well as activation of a growth pathway known as the MEK/AKT pathway. This patient displayed an impressive response to a MEK/AKT inhibitor currently in a phase I clinical study.

"Those results are quite striking considering that these are women with advanced disease," said Joyce O'Shaughnessy, M.D., who presented the data. "If MEK/AKT activation is found to be present in a substantial fraction of triple negative patients, inhibitors of this pathway could prove a significant tool in fighting this disease."

Dr. O'Shaughnessy is medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research; a practicing oncologist with Texas Oncology; and the Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center.

"This is among the largest studies of a single tumor type in which whole genome sequencing is being used to identify potential options for targeted treatment," said John Carpten, Ph.D., director of the Integrated Cancer Genomics Division at the Translational Genomics Research Institute (TGen). "As the field of genomic medicine matures, this study is sure to provide key early insights into how sequencing can best be utilized in the clinic."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our breast cancer section for the latest news on this subject. The study, titled "Next Generation Sequencing Reveals Co-Activating Events in the MAPK and PI3K/AKT Pathways in Metastatic Triple Negative Breast Cancers," is sponsored by the Translational Genomics Research Institute (TGen) and US Oncology Research with support from Life Technologies Corporation. Whole-genome sequencing of tumors and normal tissue was performed on Life Technologies' Applied Biosystems SOLiD™ platform, and results were validated in a CLIA-certified laboratory.

The Translational Genomics Research Institute

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

The Translational Genomics Research Institute. "First Genome Sequencing Clinical Trial For Triple Negative Cancer Points To New Treatments." Medical News Today. MediLexicon, Intl., 11 Dec. 2011. Web.
11 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

vineri, 9 decembrie 2011

Sequencing Of Mouse Neural Retina

Main Category: Neurology / Neuroscience
Also Included In: Eye Health / Blindness; Genetics
Article Date: 09 Dec 2011 - 1:00 PST

email to a friend printer friendly opinions Ad Banner - A new and comprehensive up-to-date ADHD resource
not yet rated
In a new study, researchers have gained fresh insights into neural disease genes by sequencing virtually all the gene expression in the mouse neural retina. The technology to obtain such a "transcriptome" has become accessible enough that full-scale sequencing is the preferred method for asking genetics questions.

The population of Eric Morrow's seminar "Neurogenetics and Disease" comprises mainly undergraduates who were skipping down the halls of their elementary schools when the first drafts of human genome sequences were published. When Morrow, assistant professor of biology, recently asked the class how to find the mutation behind a disease, a hand shot up in the back of the class to signal the answer: "Sequence the patient's genome."

Ah, to be 19 and take gene sequencing for granted. Fifteen years ago the student's answer would have been unthinkable. Five years ago, it would have been possible, but prohibitively expensive and cumbersome.

Now, armed with so-called "next-generation sequencing" technology, which brings the costs down to thousands rather than hundreds of millions of dollars, Morrow and other properly equipped researchers are obtaining detailed and comprehensive genetic sequences of cells from tissues of interest with relative ease.

In a new study, published in the journal Genomics, Morrow led a research group that has for the first time sequenced the entire "transcriptome" - all the messenger RNA transcribed from the DNA that codes proteins - of the mouse neural retina. Morrow's overall goal is to investigate the genetic nature of disease in neural tissue and sure enough, the research has yielded some intriguing clues, Morrow said. He added that he will publicly share the entire dataset.

"The reason we studied the neural retina is that we wanted to ask: Is there anything different about those genes that cause disease in the nervous system and all of the other genes in the genome," Morrow said. "There were some fairly prominent differences."

Insights in the mouse retina

The study team, including first author and postdoctoral scholar Ece Gamsiz, produced four main insights: Although only 114 of 15,251 genes are known to be associated with disease, the disease genes were disproportionately highly expressed to a statistically significant degree. Six disease genes were among the 20 most highly expressed genes, including a sweep of the top three. Disease genes also had much longer sequences on average (4,333.4 bases on average, vs. 3,323 for non-disease genes). Disease genes were somewhat, but significantly, more likely to have alternate transcripts than non-disease genes. This means that there were more different versions in RNA produced from the information encoded in DNA. Neurons in the retina expressed less than a third of the available genes for their synaptic vesicles, which are essential components for how nerve cells transmit signals. To Morrow, whose studies include the genetics of autism, the next steps have involved sequencing the transcriptomes of other neural tissues to see whether his observations from the retina are more generally true. For example, are disease-related genes unusually highly expressed elsewhere, too? And do specific neural tissues use a "synaptic vesicle" code, like the retina appears to have, or is this more specific just to retina as well?

Morrow said he's been sharing his raw transciptome data publicly so that other scientists can ask their own questions.

"When we go to meetings, people ask us about their particular genes in their particular networks," he said.

Sequencing sensation

Morrow has all but switched methods of genetic analysis. Before sequencing, scientists would use microarrays, which can be stocked with complementary strands of DNA or RNA to detect thousands of genes if they are present in a sample. But for a cost that's tens of thousands of dollars and dropping, Morrow said, sequencing allows him to see everything in the cell and learn about the entire picture, whether genes were well-known enough to be on a gene chip or not.

"You don't need to be sitting on a genome center to do this type of work anymore," Morrow said.

In a similar vein in October, colleagues at Brown and Women & Infants Hospital reported sequencing the transcriptome of human egg cells and, in another first, their sidecar-like "polar bodies." Their key insight: Expendable polar bodies reflect the gene expression of the precious eggs, making them potentially good, nondestructive indicators of which egg to choose for in vitro fertilization.

Only by seeing all the transcripts of all the genes in the mouse retina, and their full sequences, for example, could Morrow and Gamsiz have learned that disease genes are significantly longer, more likely to be transcribed in different ways, and expressed more abundantly.

"I think expression microarrays are becoming a little outdated," Morrow said. "Not that we didn't do well with them. But with them you are missing what you are not looking for because you don't know what's out there."

What makes next-generation sequencing, in this case on an Illumina Genome Analyzer IIx, work better than the slow, labor-intensive and expensive technology used for sequencing just 10 years ago is partly that it sequences a large number of DNA or RNA fragments in parallel, vastly increasing the sequencing system's throughput.

"The technology is amazing, it's a game changer," Morrow said. "In terms of molecular approaches to gene expression, genetics, and genomics it's like a new day. The data are truly beautiful."

As that metaphorical first light shines on the mouse retina transcriptome, an improved understanding of the genetics of neural disease may dawn with it.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our neurology / neuroscience section for the latest news on this subject. In addition to Morrow and Gamsiz, other authors on the paper are Qing Ouyang, Michael Schmidt, and Shailender Nagpal.
Support for the research came from the Burroughs Wellcome Fund and Brown University’s Center for Vision Research.
Brown University Please use one of the following formats to cite this article in your essay, paper or report: